Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

A pop-up exhibition in Kings Cross looks at the maddest diets ... touted as an all-natural version of the weight-loss drug by Novo Nordisk); or even dog food (which started out as a challenge ...

in the vicinity of King’s Cross, and that around 40 workers will be based at the site from Novo Nordisk’s R&D and IT divisions. The KQ cluster is in close proximity to major institutions at ...

A pop-up exhibition outside the main entrance at King’s Cross ... as an all-natural version of the weight-loss drug by Novo Nordisk); or even dog food (which started out as a challenge on ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field ... and could speak the truth to the king -- without getting their heads lopped off.

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

However, Novo Nordisk (NYSE: NVO), a pioneer in the field, remains one of the leaders. That likely won't change anytime soon, since the Denmark-based pharmaceutical giant has an excellent pipeline.

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from ...

Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But there’s still a long way to go to claw back the declines of the past ...

Finally, some good news for Novo Nordisk (NYSE: NVO) shareholders! Twice in the past two months, the Danish manufacturer of GLP-1 drugs for weight loss and diabetes treatment has reported clinical ...